Every week we review the most recent publications in women’s mental health, covering topics related to premenstrual symptoms, perinatal mood and anxiety disorders, use of medications in pregnant and breastfeeding women, perinatal substance use, and menopausal mental health.
For more detailed descriptions of many of these topics, you can sign up to receive our weekly CWMH NEWSLETTER which comes out every Thursday.
Ruta Nonacs, MD PhD
PMS AND PMDD |
| What’s Stopping Us? Using GnRH Analogs With Stable Hormone Addback in Treatment-Resistant Premenstrual Dysphoric Disorder: Practical Guidelines and Risk-Benefit Analysis for Long-term Therapy.
Wagner-Schuman M, Kania A, Barone JC, Ross JM, Mulvihill A, Eisenlohr-Moul TA. J Clin Psychiatry. 2023 Jun 21;84(4):22r14614. When first- and second-line treatments have failed to yield symptom relief, the use of GnRHa with hormone addback should be considered. |
INFERTILITY AND MENTAL HEALTH |
| No articles this week |
PSYCHIATRIC ILLNESS DURING PREGNANCY |
| Prevalence of Perinatal Depression in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
Roddy Mitchell A, Gordon H, Lindquist A, Walker SP, Homer CSE, Middleton A, Cluver CA, Tong S, Hastie R. JAMA Psychiatry. 2023 May 1;80(5):425-431.
Fernández de la Cruz L, Joseph KS, Wen Q, Stephansson O, Mataix-Cols D, Razaz N. JAMA Netw Open. 2023 Jun 1;6(6):e2318212. These cohort studies suggest that maternal OCD was associated with an increased risk of adverse pregnancy, delivery, and neonatal outcomes.
Effect of Brief Interpersonal Therapy on Depression During Pregnancy: A Randomized Clinical Trial. Hankin BL, Demers CH, Hennessey EP, Perzow SED, Curran MC, Gallop RJ, Hoffman MC, Davis EP. JAMA Psychiatry. 2023 Jun 1;80(6):539-547. In this study, brief IPT significantly reduced prenatal depression symptoms and MDD compared with enhanced usual care among pregnant individuals from diverse racial, ethnic, and socioeconomic backgrounds recruited from primary OB/GYN clinics. Gonçalves Pacheco JP, Salum G, Hoffmann MS. JAMA Psychiatry. 2023 Jun 28. The pooled prevalence of perinatal depression across all studies was 24.7% (95% CI, 23.7%-25.6%). The prevalence of perinatal depression varied slightly by country income status. The highest prevalence was found in lower-middle-income countries, with a pooled prevalence of 25.5%. In upper-middle-income countries, the pooled prevalence was 24.7% and in low-income countries, the pooled prevalence was 20.7%.
Pregnancy-Specific Anxiety Tool (PSAT): Instrument Development and Psychometric Evaluation. Bayrampour H, Hohn RE, Tamana SK, Sawatzky R, Janssen PA, Bone JN, Fairbrother N, Joseph KS. J Clin Psychiatry. 2023 Apr 19;84(3):22m14696. The area under the curve (AUC) for the diagnosis of adjustment disorders (AD) was 0.73 (95% CI, 0.67-0.79), and for AD/any anxiety disorders, the AUC was 0.80 (95% CI, 0.75-0.85). |
MEDICATIONS AND PREGNANCY |
| Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.
Dreier JW, Bjørk MH, Alvestad S, Gissler M, Igland J, Leinonen MK, Sun Y, Zoega H, Cohen JM, Furu K, Tomson T, Christensen J. JAMA Neurol. 2023 Jun 1;80(6):568-577. Prenatal exposure to lamotrigine, carbamazepine, and oxcarbazepine was not associated with an increased risk of psychiatric disorders, whereas associations were found for prenatal exposure to topiramate with attention-deficit/hyperactivity disorder (aHR, 2.38; 95% CI, 1.40-4.06) and exposure to levetiracetam with anxiety (aHR, 2.17; 95% CI, 1.26-3.72) and attention-deficit/hyperactivity disorder (aHR, 1.78; 95% CI, 1.03-3.07). Bjørk MH, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, Gilhus NE, Gissler M, Hálfdánarson Ó, Igland J, Sun Y, Tomson T, Alvestad S, Christensen J. JAMA Neurol. 2022 Jul 1;79(7):672-681. In this cohort study, prenatal exposure to topiramate, valproate, and several duotherapies were associated with increased risks of neurodevelopmental disorders. |
POSTPARTUM PSYCHIATRIC ILLNESS |
| Postpartum Psychosis or Something Else?
Madora MJ, Knopf HS, Prakash M, Kim J, Medavaram MR, Vaughn RL. Prim Care Companion CNS Disord. 2023 Jan 5;25(1):22nr03269. |
MEDICATIONS AND BREASTFEEDING |
| No articles this week |
PERINATAL SUBSTANCE USE |
| Association of Mandatory Warning Signs for Cannabis Use During Pregnancy With Cannabis Use Beliefs and Behaviors.
Roberts SCM, Zaugg C, Biggs MA. JAMA Netw Open. 2023 Jun 1;6(6):e2317138. warning signs policies were not associated with reduced cannabis use during pregnancy or with people who used cannabis believing use during pregnancy was less safe but were associated with greater support for punishment and stigma among people who did not use cannabis. |
MATERNAL MENTAL HEALTH AND CHILD OUTCOMES |
| No articles this week |
MENOPAUSE AND MENTAL HEALTH |
| Efficacy of Continuous Transdermal Nitroglycerin for Treating Hot Flashes by Inducing Nitrate Cross-tolerance in Perimenopausal and Postmenopausal Women: A Randomized Clinical Trial.
Huang AJ, Cummings SR, Ganz P, Schembri M, Raghunathan H, Vittinghoff E, Gibson CJ, Grady D. JAMA Intern Med. 2023 Jun 5:e231977. This randomized clinical trial found that continuous use of NTG did not result in sustained improvements in hot flash frequency or severity relative to placebo and was associated with more early but not persistent headache. |
OTHER TOPICS IN WOMEN’S MENTAL HEALTH |
| No articles this week |
Leave A Comment